Strategies in developing promising histone deacetylase inhibitors
Authors:
- 24 July 2009
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 30 (4) , 585-602
Abstract
Histone deacetylases (HDACs) are a family of enzymes that have been of interest in drug discovery for more than 30 years. Inhibitors of HDACs are potential therapeutics for various diseases, such as neurodegenerative diseases, inflammation, viral infection, and especially cancer. Most HDAC inhibitors (HDACi) are designed for cancer therapy. In 2006, suberoylanilide hydroxamic acid was approved by the US Food and Drug Administration for once‐daily oral treatment of advanced cutaneous T‐cell lymphoma. In the meantime, there have been aggressive efforts to bring HDACi to the market for every major tumor type, either as a single therapy or in combination, and a number of compounds are currently undergoing clinical trials. Multiple strategies have been applied to the rational design of drugs targeting HDACs by taking advantage of the new developments in proteomics, chemogenomics, cheminformatics, and computational chemistry/biology. Herein, we review the current methods successfully used in developing novel HDACi. © 2009 Wiley Periodicals, Inc. Med Res Rev, 30, No. 4, 585–602, 2010Keywords
This publication has 105 references indexed in Scilit:
- Residues in the 11 Å Channel of Histone Deacetylase 1 Promote Catalytic Activity: Implications for Designing Isoform-Selective Histone Deacetylase InhibitorsJournal of Medicinal Chemistry, 2008
- Total Synthesis and Biological Mode of Action of Largazole: A Potent Class I Histone Deacetylase InhibitorJournal of the American Chemical Society, 2008
- Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractilityGenes & Development, 2007
- HDAC6 Modulates Cell Motility by Altering the Acetylation Level of CortactinMolecular Cell, 2007
- Activity-based probes for proteomic profiling of histone deacetylase complexesProceedings of the National Academy of Sciences, 2007
- Negative and Positive Regulation of Gene Expression by Mouse Histone Deacetylase 1Molecular and Cellular Biology, 2006
- Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancerNature Reviews Cancer, 2006
- SIRT1 Regulates HIV Transcription via Tat DeacetylationPLOS Biology, 2005
- Molecular dynamics simulations of biomoleculesNature Structural & Molecular Biology, 2002
- CHARMM: A program for macromolecular energy, minimization, and dynamics calculationsJournal of Computational Chemistry, 1983